Marshall Nash

3.4k total citations
7 papers, 361 citations indexed

About

Marshall Nash is a scholar working on Neurology, Molecular Biology and Pharmacology. According to data from OpenAlex, Marshall Nash has authored 7 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Neurology, 2 papers in Molecular Biology and 2 papers in Pharmacology. Recurrent topics in Marshall Nash's work include Botulinum Toxin and Related Neurological Disorders (2 papers), Pharmacovigilance and Adverse Drug Reactions (1 paper) and Animal Nutrition and Physiology (1 paper). Marshall Nash is often cited by papers focused on Botulinum Toxin and Related Neurological Disorders (2 papers), Pharmacovigilance and Adverse Drug Reactions (1 paper) and Animal Nutrition and Physiology (1 paper). Marshall Nash collaborates with scholars based in United States, Canada and Ethiopia. Marshall Nash's co-authors include Javed Butler, Louise J. Short, Norman Gitlin, Sebastian Schneeweiß, Neal Osborn, Charles Wilmer, Brian F. Gage, Gregory J. Esper, Peter Wahl and Keith Rodgers and has published in prestigious journals such as Stroke, Journal of Neurotrauma and Pharmacoepidemiology and Drug Safety.

In The Last Decade

Marshall Nash

6 papers receiving 351 citations

Peers

Countries citing papers authored by Marshall Nash

Since Specialization

Citations

This map shows the geographic impact of Marshall Nash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marshall Nash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marshall Nash more than expected).

Fields of papers citing papers by Marshall Nash

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marshall Nash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marshall Nash. The network helps show where Marshall Nash may publish in the future.

Co-authorship network of co-authors of Marshall Nash

This figure shows the co-authorship network connecting the top 25 collaborators of Marshall Nash. A scholar is included among the top collaborators of Marshall Nash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marshall Nash. Marshall Nash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease 2025 ·The Journal of Prevention of Alzheimer s Disease ·David Greeley, Marshall Nash, (unknown), (unknown), (unknown), Niels D. Prins, SangYun Kim, (unknown), Jonathan A. Busam, (unknown), (unknown), Sharon J. Sha	0
2	Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury 2015 ·Journal of Neurotrauma ·Robert D. Welch, Syed Imran Ayaz, Lawrence M. Lewis, Johan Undén, James Y. Chen, Valerie Mika, (unknown), Joseph A. Tyndall, Marshall Nash, András Büki, Pál Barzó, Dallas C. Hack, Frank C. Tortella, Kara Schmid, Ronald L. Hayes, Arastoo Vossough, (unknown), Jeffrey J. Bazarian	121
3	Safety and efficacy of ranirestat in patients with mild‐to‐moderate diabetic sensorimotor polyneuropathy 2015 ·Journal of the Peripheral Nervous System ·Michael Polydefkis, Joseph C. Arezzo, Marshall Nash, Vera Bril, Aziz Shaibani, Robert J. Gordon, (unknown), Roderick Junor, (unknown)	19
4	Abstract 150: Dalfampridine in Patients With Chronic Post-Ischemic Stroke Deficits: Results From a Phase 2 Study 2014 ·Stroke ·David M. Simpson, Michael Reding, Marshall Nash, Scott E. Kasner, Gustavo Cruz, Ping Zhao, Herbert R. Henney, Adrián L. Rabinowicz, Enrique Carrazana	2
5	Validation of claims‐based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially‐insured population 2010 ·Pharmacoepidemiology and Drug Safety ·Peter Wahl, Keith Rodgers, Sebastian Schneeweiß, Brian F. Gage, Javed Butler, Charles Wilmer, Marshall Nash, Gregory J. Esper, Norman Gitlin, Neal Osborn, Louise J. Short, Rhonda L. Bohn	142
6	Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1) 2004 ·Stroke ·Marian P. LaMonte, Marshall Nash, David Z. Wang, Andrew R. Woolfenden, John R. Schultz, Marcie J. Hursting, Philip M. Brown	72
7	Temperature-induced changes in fatty acid composition of myelinated and non-myelinated axon phospholipids 1986 ·Comparative Biochemistry and Physiology Part B Comparative Biochemistry ·Kenneth J. Friedman, Dexter M. Easton, Marshall Nash	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact